Who is sponsoring NCT03706339?

NCT03706339 is sponsored by Aswan University Hospital.

What drugs are being tested in NCT03706339?

Interventions in NCT03706339: normal saline arm group, intravenous tranexamic acid, Topical tranexamic acid.

What condition does NCT03706339 study?

NCT03706339 studies Cesarean Section Complications.

Is NCT03706339 still recruiting?

NCT03706339 is currently completed. Last updated 5 August 2020.

Last reviewed 2020-08-05 · How we verify

NCT03706339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing Blood Loss During Cesarean Section by Topical Versus IV Tranexamic Acid

Completed NA Last updated 5 August 2020

What this trial tests

NA trial testing normal saline arm group in Cesarean Section Complications in 450 participants. Completed in 1 August 2020.

Timeline

1 November 2018

Primary endpoint
31 March 2020

1 August 2020

Quick facts

Lead sponsor	Aswan University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	450
Start date	1 November 2018
Primary completion	31 March 2020
Estimated completion	1 August 2020
Sites	1 location across Egypt

Drugs / interventions tested

normal saline arm group
intravenous tranexamic acid — full drug profile →
Topical tranexamic acid — full drug profile →

Conditions studied

Cesarean Section Complications — all drugs for Cesarean Section Complications →

Sponsor

Aswan University Hospital

Who can join

Adults 20 to 45, female only, with Cesarean Section Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tranexamic (TXA)acid is an inexpensive, antifibrinolytic drug long used to control bleeding due to surgery, menorrhagia, or trauma. Additionally, tranexamic acid has been shown to reduce bleeding during cesarean delivery as well as the need for additional uterotonic agents, albeit to a minimal degree. However, previous studies have been performed only in women with a standard risk for postpartum hemorrhage( PPH) and have not focused on assessing the effects of tranexamic acid in high-risk women. The aim of this study is to evaluate the efficacy of IV versus topical application of tranexamic acid in reducing blood loss during and after elective C.S. The Research Question Is topical application of Tranexamic acid effective in reducing blood loss during and after an elective Caesarean section? The Research Hypothesis the TXA could be able to reduce blood loss during and after elective Caesarean section. The null hypothesis will, therefore, state that: There will be no difference between topical and IV TXA and placebo in reducing blood loss during and after elective Caesarean section.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cesarean Section Complications

Currently open trials in the same condition.

NCT07278037 — Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage · recruiting
NCT05224726 — Platelet Rich Plasma for Uterine Scar · NA · recruiting
NCT07130747 — Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section · NA · recruiting
NCT05791630 — The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) · NA · recruiting
NCT07049705 — Factors Influencing Bradycardia During Spinal Anesthesia in Obstetric Patients Undergoing Cesarean Section · active not recruiting

Other Aswan University Hospital trials

Trials by the same sponsor.

NCT06491394 — Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats · Phase 4 · completed
NCT06211088 — Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting · NA · completed
NCT06583590 — Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction · Phase 2, PHASE3 · recruiting
NCT06537323 — Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl · NA · recruiting
NCT06535256 — Compare Intraperitoneal Instillation of Bupivacaine+dexmedetomidine Versus Bupivacaine+dexamethasone on Postoperative Pa · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03706339 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aswan University Hospital
Last refreshed: 5 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03706339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing